Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Euroz Hartleys Healthcare Conference 2026
20 slides from Argenica Therapeutics's conference presentation, February 2026
Slide 1: Argenica Therapeutics Investor Presentation
Advancing novel neuroprotective therapies for severe ARGENICA THERAPEUTICS brain injury across a range of neurological disorders INVESTOR PRESENTATION EUROZ HARTLEY’S HEALTHCARE CONFERENCE FEBRUARY 2026 MANAGING DIRECTOR PRESENTATION 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Neuroprotection: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 4: Breakthrough Neuroprotective Therapy
BREAKTHROUGH NEUROPROTECTIVE THERAPY MISSION ABOUT ARG-007 Commercialise neuroprotective treatments that minimises brain damage and optimised recovery Efficacy shown in Phase 2 stroke trial following stroke & other neurological conditions ARGENICA THERAPEUTICS Clear patient responder group identifie
Slide 5: ARG-007's Unique Mechanism of Action to Reduce Multiple Causes of Brain Injury
ARG-007’S UNIQUE MECHANISM OF ACTION TO REDUCE MULTIPLE CAUSES OF BRAIN INJURY ARGENICA THERAPEUTICS 5 Values in graphic approximated from Edwards et al., Mol Brain 2018 11(1):8 and Chiu et al., 2020. Curr Ther Res Clin Exp. 19:92:100584 for illustrative purposes www.argenica.com.au
Slide 6: Our Lead Indications
OUR LEAD INDICATIONS DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 2b Efficacy Safety / Tox Safety Safety/Efficacy Efficacy/Safety STROKE – ARG-007 Damage to the brain from interruption of its blood supply MOD-SEVERE TBI – ARG-007 ARGENICA THERAPEUTICS Trauma to the head or body causes a loss of cons
Slide 7: Key Company Metrics
KEY COMPANY METRICS $5M $35M $4M CASH @ BANK 1 MARKET CAP2 R&D Tax Rebate ARGENICA THERAPEUTICS 128.1M 37% SHARES HELD BY TOP 20 +ve DATA SHARES ON ISSUE IN PHASE 2 STROKE TRIAL 1. Cash balance as @ 31 December 2025 7 2. Calculated with closing price on @4th February 2026 being $0.285 www.argenica.c
Slide 8: Ischaemic Stroke Opportunity
ISCHAEMIC STROKE ARGENICA THERAPEUTICS OPPORTUNITY 8 www.argenica.com.au
Slide 9: Stroke Has the Greatest Incidence of Disability and Death of All Neurological Conditions
STROKE HAS THE GREATEST INCIDENCE OF DISABILITY AND DEATH OF ALL NEUROLOGICAL CONDITIONS1 • Stroke is the leading neurological cause of long-term disability and death, significantly greater than other leading neurological conditions. • Stroke-related costs in the United States came to nearly $56.5 b
Slide 10: This Represents a Huge Unmet Need
Number of stroke victims each year globally 1 THIS REPRESENTS A HUGE UNMET NEED 5m 4.5m 4m ~5 MILLION PEOPLE AIS Drug Treatment market valued at $10.6 Billion by 2027 1. suffering from an acute ischaemic stroke globally each year1 3.5m Current standard of care treatments for more severe stroke ARGEN
Slide 11: Phase 2 Trial Outcomes
PHASE 2 TRIAL ARGENICA THERAPEUTICS OUTCOMES 11 www.argenica.com.au
Slide 12: Successful Phase 2 Trial
SUCCESSSFUL PHASE 2 TRIAL PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of PATIENT OUTCOME MEASURES patients to meet inclusion 0.3mg/kg ARG-007 or ARG-007 APPEARS SAFE & WELL TOLE
Slide 13: Overview of Phase 2 Trial Results
OVERVIEW OF PHASE 2 TRIAL RESULTS Argenica’s Phase 2 trial for ARG-007 in AIS has met its primary endpoint, missed on its overall secondary endpoint, but showed encouraging signal of efficacy in the “slow collateral” patients. KEY SUMMARY – TOPLINE DATA • 15% infarct volume (brain injury) reduction
Slide 14: Post-hoc AI Data Analysis Reveals Strong Efficacy in Severe Stroke Patients
POSTHOC AI DATA ANALYSIS REVEALS STRONG EFFICACY IN SEVERE STROKE PATIENTS POSTHOC DATA ANALYSIS • Collaboration with AI Company Brainomix to correct for misdiagnosed stroke severity ARGENICA THERAPEUTICS revealed true efficacy of ARG-007 in severe stroke patients. • ARG-007 delivered statistically
Slide 15: ARG-007 Significantly Reduces Expansion of Damaged Brain in More Severe Stroke Patients
ARG-007 significantly reduces expansion of damaged brain in more severe stroke patients ARGENICA THERAPEUTICS Figure 1: Total corrected ischaemic lesion volumes (cISC) in ml as predicted from the corresponding multivariate model across different baseline AIV values (0ml, 10ml, 20ml; 30 ml). The esti
Slide 16: ARG-007 Significantly Improved Disability Outcomes in Patients with More Severe Strokes
ARG-007 significantly improved disability outcomes in patients with more severe strokes ABLE TO WALK WITHOUT ASSISTANCE ARGENICA THERAPEUTICS Figure 1: Distribution of the mRS at 90 days across treatment arms using e-ASPECTS or AIV to exclude patients with small infarct cores alongside patients with
Slide 17: Phase 2 Data Confirms Commercially Attractive, High-Value Patient Population
PHASE 2 DATA CONFIRMS COMMERCIALLY ATTRACTIVE, HIGH-VALUE PATIENT POPULATION With validated human efficacy in a high-need stroke population, Argenica has transitioned into a clinically and commercially attractive late-stage opportunity AI analysis accurately determined patient Precision-defined resp
Slide 18: Next Steps
NEXT STEPS PHARMA PARTNER DISCUSSIONS: ARG-007 is now a further derisked asset with efficacy signals in a clearly defined patient population. This refined narrative makes the opportunity more compelling for big pharma/biotech partners who want de- risked assets. Significant efforts will be made in e
Slide 19: Potential Catalysts for 2026
POTENTIAL CATALYSTS FOR 2026 H1 Paediatric Plan Waiver from European Medicines Agency for ARG-007 in Stroke 2026 R&D Tax Rebate Board Changes Completion of FDA requested in vitro assays for IND Updated clinical development strategy for Stroke & TBI ARGENICA THERAPEUTICS European Stroke O
Slide 20: Argenica Therapeutics Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 20 www.argenica.com.au
Argenica Therapeutics — Euroz Hartleys Healthcare Conference 2026 on 6ix